Olema Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Olema Pharmaceuticals, Inc. on August 13, 2026. The filing discloses the appointment of a new Chief Financial Officer and related compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $545,000 annualized.
- Target Bonus: 45% of annual base salary.
- Sign-on Bonus: $350,000 total ($250,000 within 30 days; $100,000 after one year).
- Equity Grant: Option to purchase 650,000 shares of common stock, vesting over four years (25% cliff, then monthly).
Material Changes
The primary material change is the appointment of Jason O'Byrne as Chief Financial Officer, effective August 11, 2026. Mr. O'Byrne joins from Vir Biotechnology, Inc., where he served as CFO from October 2024 to August 2026. He brings prior experience as CFO of Caribou Biosciences and senior finance roles at Audentes Therapeutics and Genentech/Roche.
Outlook, Risks, and Contingencies
The filing outlines specific severance contingencies tied to the new CFO's employment:
- Change in Control: If terminated without Cause or resigns for Good Reason within 3 months prior to or 18 months after a Change in Control, the executive receives 12 months of base salary plus target bonus, prorated bonus, accelerated vesting of all unvested equity, and 12 months of COBRA.
- Standard Termination: If terminated without Cause or resigns for Good Reason outside the Change in Control window (after 12 months of service), the executive receives 12 months of base salary, prorated bonus, 50% accelerated vesting of unvested options, and 12 months of COBRA.
Investor Verification Checklist
- Verify the impact of the $350,000 sign-on bonus on the company's immediate cash burn rate.
- Review the full text of the Offer Letter (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Assess the dilution impact of the 650,000 share option grant relative to the current outstanding share count.
- Confirm the company's cash position to ensure it can support the new executive's compensation package and ongoing operations.